Condition
Mantle Cell Lymphoma Recurrent
Total Trials
5
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
60.0%
3 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Terminated3
Unknown1
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT04234061Phase 2Active Not RecruitingPrimary
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
NCT05645744Terminated
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
NCT05360238Phase 1Terminated
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
NCT02086591Phase 2Terminated
A Phase II Study of Doxycycline in Relapsed NHL
NCT01322776Phase 1UnknownPrimary
Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma
Showing all 5 trials